Zydus Lifesciences completes merger making Asserto a wholly owned subsidiary
Zydus Lifesciences · Pharmaceuticals & Biotechnology
Key highlights
- Zara Merger Sub Inc., a wholly owned subsidiary of Zydus, merged into Nasdaq-listed Asserto Holdings Inc. on June 16, 2026
- Zydus acquired all outstanding Asserto shares for USD 23.50 per share, totaling USD 166.33 million in cash
- Post-merger, Asserto's common stock is delisted from Nasdaq and it operates as a wholly owned subsidiary of Zydus Lifesciences
Why it's rated notable: amount is ₹500 crore or more
Original filing
Completion Of Merger Of Assertio Holdings Inc.
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Zydus Lifesciences
- Acquisition / mergerMajor development· Adverse for the businessZydus Lifesciences reports unaudited results for quarter ended September 30, 2026
- Acquisition / mergerNotableZydus Lifesciences completes acquisition of Sterling Biotech's API business
- Acquisition / mergerNotableZydus Lifesciences completes acquisition of Assertio Holdings on June 16, 2026
- Dividend / buyback / bonusNotableZydus Lifesciences Q4 FY26 adjusted net profit up 14.6%; buyback up to Rs. 11,000 mn
- Acquisition / mergerNotableZydus Lifesciences to acquire Assertio Holdings via $166.4M cash tender offer
Other acquisition / merger filings this fortnight
- IndiGrid Infrastructure Trust Q2 FY27 Earnings Conference Call Transcript Released
- Cubical Financial Services Ltd announces promoter reclassification post open offer
- Novus Loyalty Limited approves acquisition of AutoPe Payment Solutions via share swap
- Shish Industries Limited files Composite Scheme of Amalgamation proposal
- Jubilant Ingrevia Limited updates on acquisition of 40% stake in Zettaone Technologies
- NHC Foods approves quarter results, 99.98% Sachmaas Foods investment, two appointments
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.